Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 1/2020

01-03-2020 | Cytostatic Therapy | Case Report

Hepatoblastoma in a Young Adult: a Rare Case Report and Review of the Literature

Authors: Jeewan Ram Vishnoi, Ajai Sasidhar, Sanjeev Misra, Puneet Pareek, Sudeep Khera, Sushil Kumar, Ankit Jain

Published in: Journal of Gastrointestinal Cancer | Issue 1/2020

Login to get access

Excerpt

Hepatoblastoma is the most common primary liver malignant neoplasm occurring under the age of 2 years. Hepatoblastoma is considered to arise during the embryogenesis; it is derived from pluripotent hepatic stem cells [1]. The pathogenesis is related to deranged liver organogenesis, and often the tumor recapitulates the stages of liver development [2]. Therefore, approximately 90% of the cases occur under the age of 5 years [3], and the median age of presentation is between 16 and 18 months. The occurrences of the hepatoblastoma in the young adult or middle age are extremely rare and have a poor prognosis. A 2016 extensive literature review by Celotti et al. [4], which analyzed all the cases of hepatoblastoma in adults reported in English, as well as other languages, found only 63 cases including only two case reports from India [5]. Here, we report a case of hepatoblastoma in an 18-year-old girl to highlight the atypical age and presentation of the disease. …
Literature
11.
go back to reference Urdiain G, Sánchez Acedo P, Mateo Retuerta J, Castilla T, Ripa Z, Herrera Cabezón J. notas clínicas0 Hepatoblastoma del adulto. Presentación de un caso Adult hepatoblastoma. A case report. An Sist Sanit Navar. 2016;39:301–4. Urdiain G, Sánchez Acedo P, Mateo Retuerta J, Castilla T, Ripa Z, Herrera Cabezón J. notas clínicas0 Hepatoblastoma del adulto. Presentación de un caso Adult hepatoblastoma. A case report. An Sist Sanit Navar. 2016;39:301–4.
13.
go back to reference Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:2665–75. https://doi.org/10.1200/JCO.2000.18.14.2665.CrossRefPubMed Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:2665–75. https://​doi.​org/​10.​1200/​JCO.​2000.​18.​14.​2665.CrossRefPubMed
15.
go back to reference Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004;42:74–83. https://doi.org/10.1002/pbc.10376.CrossRefPubMed Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004;42:74–83. https://​doi.​org/​10.​1002/​pbc.​10376.CrossRefPubMed
Metadata
Title
Hepatoblastoma in a Young Adult: a Rare Case Report and Review of the Literature
Authors
Jeewan Ram Vishnoi
Ajai Sasidhar
Sanjeev Misra
Puneet Pareek
Sudeep Khera
Sushil Kumar
Ankit Jain
Publication date
01-03-2020
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 1/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00256-3

Other articles of this Issue 1/2020

Journal of Gastrointestinal Cancer 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.